Jefferies advised on Apogee Therapeutics' sale to AbbVie
The $10.9 billion deal is the largest biotech deal of 2026 and the largest pre-Phase 3 acquisition ever.
See the latest news and media coverage for Jefferies. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global investment banking and capital markets firm
jefferies.comLast updated
In short: Jefferies expanded its advisory footprint and executive team while navigating complex global market shifts in AI, energy, and emerging markets.
The $10.9 billion deal is the largest biotech deal of 2026 and the largest pre-Phase 3 acquisition ever.
The IPO is the largest on the Toronto Stock Exchange since 2021 and the largest healthcare IPO in TSX history.
The deal involved Figure acquiring Kiavi's platform and a joint venture with Sixth Street acquiring its balance sheet assets.
The strong labor market forces investors to reconsider Federal Reserve rate cuts of at least 50 basis points starting this fall.
Jefferies Financial faces ongoing lawsuits and investment losses tied to fraud in private credit. Read why I view JEF stock as a Hold at this...
Investing.com -- UBS downgraded Jefferies Financial Group to "neutral" from "buy" on Thursday, saying the stock’s recent rally has left little room for further gains...
Jefferies (JEF) doesn't possess the right combination of the two key ingredients for a likely...
Jefferies Financial Group Inc. (NYSE: JEF) today announced it will release its second quarter financial results on Wednesday, June 24, 2026 after market close.
Track Jefferies and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Jefferies and other trending companies.